​Moderna Shares Tumble As R&D Cuts Follow COVID Business Slump – Tyler Durden

Moderna Shares Tumble As R&D Cuts Follow COVID Business Slump Moderna’s post-pandemic future remains highly uncertain. The company revealed new plans to slash $1.1 billion in expenses by 2027 to steer toward profitability. This comes a little over a month after investors were left disappointed following management’s outlook cut on slumping vaccine sales amid a sliding Covid business.  “Moderna’s broad clinical success and recent commercial challenges necessitate a more selective and paced approach to its research and development investment. Through portfolio prioritization and cost efficiencies, the company expects to reduce annual research and development expense by approximately $1.1 billion starting in…  — Continue at ZeroHedge News : Read More